SAN DIEGO, May 21, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the United States ("U.S.") Food and Drug Administration ("FDA") has granted the Company's request for a Type C meeting to obtain regulatory guidance from the agency for Femprox®, the Company's topical alprostadil cream for the treatment for female sexual arousal disorder (FSAD). The meeting is expected to take place in late July 2012 and the purpose of the meeting is to obtain feedback from the agency regarding the suitability of Femprox®'s clinical, preclinical, and quality control data to support a New Drug Approval ("NDA") in the U.S.
